FDA Grants Orphan Drug Designation to BlueRock Therapeutics' Investigational Cell Therapy OpCT-001
January 23, 2026
January 23, 2026
WHIPPANY, New Jersey, Jan. 23 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news:
* * *
FDA grants Orphan Drug Designation to BlueRock Therapeutics' investigational cell therapy OpCT-001
* Designation is for treating retinitis pigmentosa, one of the most common types of inherited retinal diseases characterized by the loss of photoreceptor cells
* OpCT-001 is . . .
* * *
FDA grants Orphan Drug Designation to BlueRock Therapeutics' investigational cell therapy OpCT-001
* Designation is for treating retinitis pigmentosa, one of the most common types of inherited retinal diseases characterized by the loss of photoreceptor cells
* OpCT-001 is . . .